دورية أكاديمية

Indicaciones de los inhibidores de PCSK9 en la práctica clínica. Recomendaciones de la Sociedad Española de Arteriosclerosis (SEA), 2019

التفاصيل البيبلوغرافية
العنوان: Indicaciones de los inhibidores de PCSK9 en la práctica clínica. Recomendaciones de la Sociedad Española de Arteriosclerosis (SEA), 2019
المؤلفون: Ascaso, Juan F, Civeira, Fernando, Guijarro, Carlos, López Miranda, José, Masana, Luis, Mostaza, José Maria, Pedro-Botet, Juan, Pintó, Xavier, Valdivielso, Pedro, Universitat Autònoma de Barcelona
سنة النشر: 2019
المجموعة: Universitat Autònoma de Barcelona: Dipòsit Digital de Documents de la UAB
مصطلحات موضوعية: Inhibidores de la proproteína convertasa subtilisina kexina 9, Colesterol, Lipoproteínas de baja densidad, Tratamiento, Indicaciones clínicas, Hipercolesterolemia familiar, Enfermedad cardiovascular, Documento de consenso, Número necesario a tratar, Proprotein convertase subtilisin kexin 9 inhibitors, Low density lipoprotein, Treatment, Clinical indications, Familial hypercholesterolemia, Cardiovascular disease, Consensus document, Number needed to treat
الوصف: A group of experts convened by the Spanish Society of Arteriosclerosis (SEA) has been in charge of updating the SEA document on the indications of PCSK9 inhibitors (PCSK9i) in clinical practice that was published in 2016. This update is justified by the fact that the data from clinical trials carried out on a large scale with PCSK9i have shown that in addition to their high potency to lower atherogenic cholesterol, they reduce the risk of atherosclerotic cardiovascular disease, both in patients with stable disease, and with recent disease, and with a high degree of security. This update provides the recommendations and level of evidence for the prescription of iPCSK9 in patients with homozygous and heterozygous familial hypercholesterolemia, with atherosclerotic cardiovascular disease, and in primary prevention in patients with very high cardiovascular risk. These recommendations have been established taking into account the concentration of LDL-C, the clinical situation of the patient, the additional risk factors and the cost-effectiveness of their use.
نوع الوثيقة: article in journal/newspaper
وصف الملف: application/pdf
اللغة: Spanish; Castilian
تدمد: 15781879
العلاقة: Clinica e Investigacion en Arteriosclerosis; Vol. 31 Núm. 3 (mayo 2019), p. 128-139; https://ddd.uab.cat/record/222686Test; urn:10.1016/j.arteri.2019.04.002; urn:oai:ddd.uab.cat:222686; urn:scopus_id:85066075140; urn:articleid:15781879v31n3p128; urn:oai:egreta.uab.cat:publications/5656afc1-a057-4d20-afc7-cc6d10724dcc; urn:pmid:31130361
الإتاحة: https://ddd.uab.cat/record/222686Test
حقوق: open access ; Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. ; https://creativecommons.org/licenses/by-nc-nd/4.0Test/
رقم الانضمام: edsbas.354A119D
قاعدة البيانات: BASE